Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | PI4KA | P42356 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.50 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 8/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11457829 | 0.91 | ADORA2A (0.54) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL460736 | 0.91 | TP53 (0.55) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL567355 | 0.90 | ADORA2A (0.55) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL29809280 | 0.90 | ADORA2A (0.55) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL2198652 | 0.90 | TP53 (0.52) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL14415240 | 0.87 | TP53 (0.49) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL31124744 | 0.86 | ADORA2A (0.56) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL2197488 | 0.86 | ADORA2A (0.56) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL2200805 | 0.85 | ADORA2A (0.59) | TP53CYP2C9NFKB1MAPK1HSD17B10 | |
| SCHEMBL11458579 | 0.84 | TP53 (0.57) | TP53CYP2C9NFKB1MAPK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2125792-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| US-20090131458-A1 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-05-21 | — | — | US | disclosed |
| WO-2008101867-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | TP53 422/4885CYP2C9 3964/4885NFKB1 153/4885 |
| US-20090131458-A1 | Compounds | LTC4S, LTB4R2, LTB4R | TP53 422/4885CYP2C9 3964/4885NFKB1 153/4885 |
| US-20100120799-A1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | LTC4S, STING1, LTB4R2 | TP53 668/4885CYP2C9 244/4885NFKB1 339/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | TP53 422/4885CYP2C9 3964/4885NFKB1 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.